Who is eligible for clinical trial NCT07085039?

Participants must meet protocol criteria for Castleman's Disease (CD). Confirm exact inclusion and exclusion requirements with the study coordinator.

Does clinical trial NCT07085039 provide travel or cost reimbursement?

Check with the site coordinator at the participating facility for travel and lodging stipend availability, and for which routine-care costs are covered.

🏛️ Verified NIH Record • Updated 2026-04-21

Ruxolitinib in Previously Treated Idiopathic Multicentric Castleman Disease (NCT07085039)

🟢 Recruiting Phase2 💊 Investigational Drug / Biologic Sponsor: University of Pennsylvania

🩺 Plain-English Summary (8th-Grade Level)

The research study is being done to look at the effects of ruxolitinib in adults with idiopathic Multicentric Castleman Disease (iMCD) that has not gotten better from taking siltuximab or tocilizumab, or who cannot take those medications.

Who can join: To join this study, participants generally need to meet the listed inclusion criteria (7 items) and avoid the listed exclusions (35 items).

Location: University of Pennsylvania — Philadelphia, Pennsylvania

📋 "Do I Qualify?" — 1-Minute Self Screener

Instant Checklist

Check every box below. If you can check all of them, you may meet the study's basic screening requirements (final eligibility is confirmed by the site team).

Male or female, age 18-80
Documented disease history consistent with diagnostic criteria for iMCD
Indication of clinico-histopathological features consistent with iMCD as determined by a licensed pathologist in a diagnostic pathology report, or a CAS grade of at least 3 in the companion registry study (ACCELERATE).
Refractory (patient did not achieve sufficient disease control with anti-IL-6 therapy, as determined by the site investigator), relapsed (return of symptoms while on therapy), or inability to tolerate anti-IL-6 or anti-IL-6 receptor therapy
Evidence of active disease, defined by at least two of: constitutional symptoms (fatigue, night sweats, fever, weight change), hemoglobin \< lower limit of normal, C-reactive protein \> upper limit of normal (or \>10 mg/L), or albumin \< lower limit of normal (\<3.5 g/dL), at lease one lymph node meeting modified Cheson criteria
Ability to consume oral medication in the form of a tablet
Ability to provide informed consent prior to any study-specific activities

Usually NOT eligible if any of the following apply:

Exclusion Criteria:
Subjects cannot be pregnant or nursing females
Women of childbearing potential must have a negative pregnancy test documented at the Baseline Visit. Subjects of reproductive potential may not participate unless they have agreed, as part of the informed consent, to use an effective contraceptive method for the duration of the study and for at least 12 weeks after ending treatment
Subjects cannot have received any systemic therapy(ies) intended to treat iMCD other than corticosteroids or anti-IL-6 therapy within 14 days of enrollment
Corticosteroid treatment must have been initiated more than 28 days prior to enrollment and be maintained at a stable or tapering dose (prednisone or equivalent up to 1 mg/kg/day) prior to enrollment; dose cannot be elevated for the duration of the study but can be maintained or tapered
For subjects who cannot or are unwilling to undergo a 14-day washout period from their anti-IL-6 therapy: i. Anti-IL-6 therapy may be permitted if the subject has been on therapy for at least 3 months, no toxicity has been documented, and sufficient disease control is not achieved ii. Anti-IL-6 therapy is recommended to be discontinued within the first 6 weeks after starting ruxolitinib
Subjects cannot have previously received ruxolitinib monotherapy or combination therapy to treat iMCD
Subjects cannot have uncontrolled infection or infectious disease(s) that is/are exclusionary for / mimickers of iMCD
Fungal disease must be stable for at least two weeks before enrollment
Subjects with history of recent bacteremia must have a documented negative blood culture before enrollment
Subjects with past history of non-therapy related opportunistic infection should discuss eligibility and possible immunologic evaluation with the licensed site investigator prior to enrollment
Subjects cannot have:

🔍 Extracted verbatim from the official NIH eligibility criteria. Always confirm with the study coordinator.

📍 All Participating Trial Locations (1 Sites)

University of Pennsylvania — Philadelphia, Pennsylvania

💰 Cost, Insurance & Patient Rights

100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

🏛️ View Official NIH Record ↗